Tissue inhibitor of metalloproteinase-2 inhibits ameloblastoma growth in a new mouse xenograft disease model

Journal of Oral Pathology and Medicine

Volumn 39, Issue 1, 2010, Pages 94-102

  Zhang, L ^a   Zeng, D ^a   Huang, H ^a   Wang, J ^a   Tao, Q ^a   Pan, C ^a   Xu, J ^a   Zhang, B ^a   Wang, A ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Ameloblastoma; Matrix metalloproteinase 2; Tissue inhibitor of metalloproteinase 2; Xenograft

Indexed keywords

COMPLEMENTARY DNA; GELATINASE A; GREEN FLUORESCENT PROTEIN; PLASMID DNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AMELOBLASTOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER MODEL; CONTROLLED STUDY; FEMALE; GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RNA ANALYSIS; TIMP 2 GENE; TUMOR XENOGRAFT; VALIDATION PROCESS;

ADULT; AMELOBLASTOMA; ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VECTORS; HUMANS; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOFT TISSUE NEOPLASMS; SUBCUTANEOUS TISSUE; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 76249120429     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2009.00812.x     Document Type: Article

References (42)

1. Barnes L, Eveson JW, Reichart P, Sidransky D, eds. World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. IARC Press : Lyon 2005.
2. Gardner DG. Some current concepts of the pathology of ameloblastomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 82 : 660 669.
3. Torres-Lagares D, Infante-Cossío P, Hernández-Guisado JM, et al. Mandibular ameloblastoma: a review of the literature and presentation of six cases. Med Oral Pathol Oral Cir Bucal 2005 10 : 231 238.
4. Klostergaard J, Auzenne E, Ghosh S, et al. Magnetic resonance imaging-based prospective detection of intraperitoneal human ovarian carcinoma xenografts treatment response. Int J Gynecol Cancer 2006 16 (Suppl. 1 111 117.
5. Migaldi M, Sartori G, Rossi G, Cittadini A, Sgambato A. Tumor cell proliferation and microsatellite alterations in human ameloblastoma. Oral Oncol 2008 44 : 50 60.
6. Campbell D, Jeffrey RR, Wallis F, et al. Metastatic pulmonary ameloblastoma. An unusual case. Br J Oral Maxillofac Surg 2003 41 : 194 196.
7. Kim S, Prichard CN, Younes MN, et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res 2006 12 : 600 607. (Pubitemid 43166155)
8. Zhang B, Huang HZ, Tao Q, et al. Establishment and biological behavior of human ameloblastoma xenograft in nude mice. China J Oral Maxillofacial Surg 2004 2 : 270 273.
9. Zhang LT, Huang HZ, Zeng DL, et al. Construction of human subcutaneous ameloblatoma xenograft in nude mice. W China J Stomatol 2007 25 : 12 4.
10. Shi Z, Liang YJ, Chen ZS, et al. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther 2006 5 : 39 47.
11. Ryo A, Uemura H, Ishiguro H, et al. Stable suppression of tumorigenicity by Pin1- targeted RNA interference in prostate cancer. Clin Cancer Res 2005 11 : 7523 7531.
12. Howard BA, Furumai R, Campa MJ, et al. Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res 2005 65 : 8853 8860.
13. Piva R, Chiarle R, Manazza AD, et al. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood 2006 107 : 689 697.
14. Chan DW, Ng IO. Knock-down of hepatitis B virus X protein reduces the tumorigenicity of hepatocellular carcinoma cells. J Pathol 2006 208 : 372 380.
15. Moyano JV, Evans JR, Chen F, et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006 116 : 30 2.
16. Bhakta S, Hong P, Koc O. The surface adhesion molecule CXCR4 stimulates mesenchymal stem cell migration to stromal cell-derived factor-1 in vitro but does not decrease apoptosis under serum deprivation. Cardiovasc Revasc Med 2006 7 : 19 24.
17. Kunishio K, Okada M, Matsumoto Y, et al. Matrix metalloproteinase-2 and -9 expression in astrocytic tumors. Brain Tumor Pathol 2003 20 : 39 45.
18. Tao Q, Huang HZ. The expression and significance of matrixmetalloproteinase-2 (MMP-2) in ameloblastoma [Chinese]. Kou Qian Yi Xue Za Zhi 2000 10 : 325 326.
19. Visscher DW, Höwyhtä M, Ottosen SK, et al. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 1994 59 : 339 344.
20. Zhang B, Huang HZ, Tao Q, et al. Association of matrix metalloproteinase-2 activity with cell proliferation and growth in ameloblastoma [Chinese]. Hua Xi Kou Qiang Yi Xue Za Zhi 2006 24 : 7 10.
21. Zeng DL, Huang HZ, Zhang B, et al. Expression of MMP- 2 in ameloblastoma cells and inhibition by RNA interference [Chinese]. Zhong Guo Kou Qiang He Mian Wai Ke Za Zhi 2005 3 : 315 319.
22. Wyatt CA, Geoghegan JC, Brinckerhoff CE. Short hairpin RNA-mediated inhibition of matrix metalloproteinase-1 in MDA-231 cells: effects on matrix destruction and tumor growth. Cancer Res 2005 65 : 11101 11108.
23. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2): a new member of the metalloproteinase inhibitor family. J Biochem 1989 164 : 17374 17378.
24. Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993 157 : 351 358.
25. Lizarraga F, Maldonado V, Meléndez-Zajgla J. Tissue inhibitor of metalloproteinases-2 growth-stimulatory activity is mediated by nuclear factor-kappa B in A549 lung epithelial cells. Int J Biochem Cell Biol 2004 36 : 1655 1663.
26. Giannelli G, Bergamini C, Marinosci F, et al. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 2002 97 : 425 431.
27. Wang A, Zhang B, Huang H, et al. Suppression of local invasion of ameloblastoma by inhibition of matrix metalloproteinase-2 in vitro. BMC Cancer 2008 8 : 182.
28. Huang HZ, Zhang LT, Zeng D, et al. The construction and expression of PcDNA3.1(+)/GFP-TIMP-2 in human ameloblastoma cell [Chinese]. Zhonghua Kou Qiang Yi Xue Za Zhi 2006 41 : 713 714.
29. Vickers RA, Gorlin RJ. Ameloblastoma: Delineation of early histopathologic features of neoplasia. Cancer 1970 26 : 699 710.
30. Céspedes MV, Casanova I, Parreño M, et al. Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol 2006 8 : 318 329.
31. Kelland LR. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 2004 40 : 827 836.
32. Meyerrose TE, Herrbrich P, Hess DA, et al. Immune-deficient mouse models for analysis of human stem cells. BioTechniques 2003 35 : 1262 1272.
33. Kumamoto H, Yamauchi K, Yoshida M, et al. Immunohistochemical detection of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in ameloblastomas. J Oral Pathol Med 2003 32 : 114 120.
34. Pinheiro JJ, Freitas VM, Moretti AI, Jorge AG, Jaeger RG. Local invasiveness of ameloblastoma. Role played by matrix metalloproteinases and proliferative activity. Histopathol 2004 45 : 65 72.
35. Kumamoto H, Ooya K. Immunohistochemical detection of MT1-MMP, RECK, and EMMPRIN in ameloblastic tumors. J Oral Pathol Med 2006 35 : 345 351.
36. Fregnani EM, Sobral LM, Alves FA, Soares FA, Kowalski LP, Coletta RD. Presence of myofibroblasts and expression of matrix metalloproteinase-2 (MMP-2) in ameloblastomas correlate with rupture of the osseous cortical. Pathol Oncol Res. 2009 15 : 231 240.
37. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000 57 : 25 40.
38. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997 91 : 439 442.
39. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003 22 : 205 222.
40. Kumamoto H, Ooya K. Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors. J Oral Pathol Med 2007 36 : 488 494. (Pubitemid 47222101)
41. Zou Z, Anisowicz A, Hendrix MJ, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994 263 : 526 529.
42. Mcgowen R, Biliran HJR, Sager R, Sheng S. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. Cancer Res 2000 60 : 4771 4778.